Danske Bank’s Adicet Bio ACET Stock Holding History

Danske Bank’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7	Hold	1	–	–	﹤0.01%	1091
2025 Q4	$8	Buy	+1	New	+$11	﹤0.01%	1486

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Danske Bank's ACET Position: Q1 2026 in Review

Danske Bank held its Adicet Bio (ACET) position steady in Q1 2026 at 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Danske Bank first reported a position in ACET in Q4 2025 and has held it in 2 quarters since. The position peaked at $8 in Q4 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

Danske Bank held 1 share of Adicet Bio worth $7 as of Q1 2026.
Danske Bank left its Adicet Bio share count unchanged in Q1 2026.
Adicet Bio made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1091 holding.
Danske Bank first reported a position in Adicet Bio in Q4 2025 and has held it in 2 quarters since.
Danske Bank's Adicet Bio position peaked at $8 in Q4 2025.
49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.